NBIX
NEUROCRINE BIOSCIENCES INC
$163.88
-2.07%
$16.8B
No data for this timeframe.
Vol
Market Cap$16.8B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (86%)
Inst. Holders10 funds
Inst. Value$3.2B
Inst. Activity2 buys / 2 sells
Insider Activity0B / 6S
Insider Net $-$44.5M
SEC Reports11
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0000914475·Prev Close $167.35
Recent Activity
Jun 4, 2026
SEC
Four NBIX C-suite insiders sold a total of $4.93M in open-market shares over a 7-day window, with the largest sales by t
CLUSTER — Impact 3/10
Jun 4, 2026
SEC
Three C-suite officers at Neurocrine Biosciences sold a total of ~$2.73M in open-market shares within a 7-day window. Al
CLUSTER — Impact 2/10
Jun 2, 2026
SEC
Three Neurocrine executives (CSO, Chief Corp. Affairs Officer, Chief Regulatory Officer) sold a total of $2.73M in open-
CLUSTER — Impact 3/10
Jun 2, 2026
Insider
Cooke Julie sold 24,965 shares
Chief Human Resources Officer @ $0.00 ($0.00)
Jun 2, 2026
Insider
Cooke Julie sold 14,214 shares
Chief Human Resources Officer @ $154.83 ($2.2M)
Jun 2, 2026
Insider
Cooke Julie sold 24,965 shares
Chief Human Resources Officer @ $81.49 ($2.0M)
Inst.
MORGAN STANLEY — TRIM
1,209,378 shares ($171.5M)
Inst.
NORGES BANK — NEW
1,146,896 shares ($162.7M)
Price Targets
$192.88
+17.7% upside
Buy
Current $163.88
Low $144.00
Median $188.00
High $250.65
29 analysts
$144.00
$250.65
Analyst Ratings
14Strong Buy
17Buy
5Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 29, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| May 22, 2026 | Bernstein | INITIATE | Outperform |
| May 8, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| May 7, 2026 | Truist Securities | MAINTAIN | Buy → Buy |
| May 6, 2026 | Citigroup | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $2.11 ▲ +9.9% | $1.67 — $2.81 | 28% YoY | 14 |
| Next Q | $3.37 ▲ +58.7% | $2.00 — $9.96 | 55% YoY | 11 |
| Current FY | $10.27 ▲ +33.8% | $8.27 — $17.37 | 61% YoY | 11 |
| Next FY | $12.71 | $8.54 — $20.06 | 24% YoY | 11 |
Latest Reports
NEUTRAL
CLUSTER
3/10
Four NBIX C-suite insiders sold a total of $4.93M in open-market shares over a 7-day window, with the largest sales by t
Jun 4, 2026
NEUTRAL
CLUSTER
2/10
Three C-suite officers at Neurocrine Biosciences sold a total of ~$2.73M in open-market shares within a 7-day window. Al
Jun 4, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $1.4B | — |
| DODGE & COX | $781.2M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $317.5M | — |
| MORGAN STANLEY | $171.5M | TRIM |
| NORGES BANK | $162.7M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 2, 2026 | Cooke Julie | M | $0.00 |
| Jun 2, 2026 | Cooke Julie | SELL | $2.2M |
| Jun 2, 2026 | Cooke Julie | M | $2.0M |
| Jun 2, 2026 | Keswani Sanjay | M | $0.00 |
| Jun 2, 2026 | Keswani Sanjay | F | $268.3K |
10 institutional holders with $3.2B total value (22,479,545 shares) as of 2025-Q4. Top holders: VANGUARD, DODGE, RENAISSANCE.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 9,700,301 | $1.4B | 43.2% | — |
| 2 | DODGE & COX | 5,508,042 | $781.2M | 24.5% | ADD +83.5% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 2,238,797 | $317.5M | 10.0% | — |
| 4 | MORGAN STANLEY | 1,209,378 | $171.5M | 5.4% | TRIM -33.8% |
| 5 | NORGES BANK | 1,146,896 | $162.7M | 5.1% | NEW |
| 6 | TWO SIGMA INVESTMENTS, LP | 984,811 | $139.7M | 4.4% | DOUBLED +183.3% |
| 7 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 850,632 | $120.6M | 3.8% | NEW |
| 8 | BANK OF AMERICA CORP /DE/ | 528,104 | $74.9M | 2.3% | TRIM -34.8% |
| 9 | WELLS FARGO & COMPANY/MN | 242,111 | $34.3M | 1.1% | — |
| 10 | FMR LLC | 70,473 | $10.0M | 0.3% | TRIM -71.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | TRIM | 1,826,937 | 1,209,378 | -33.8% | $171.5M | 2025-Q4 |
| NORGES BANK | NEW | — | 1,146,896 | — | $162.7M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 347,565 | 984,811 | +183.3% | $139.7M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 810,254 | 528,104 | -34.8% | $74.9M | 2025-Q4 |
| UBS Group AG | TRIM | 614,525 | 364,572 | -40.7% | $51.2M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 347,565 | — | $48.8M | 2025-Q3 |
| FMR LLC | TRIM | 254,844 | 72,341 | -71.6% | $10.2M | 2025-Q3 |
| NORGES BANK | EXIT | 972,856 | 0 | -100.0% | $0.00 | 2025-Q3 |
| NORGES BANK | NEW | — | 972,856 | — | $122.3M | 2025-Q2 |
| FMR LLC | DOUBLED | 95,918 | 254,844 | +165.7% | $32.0M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 10,202 | 0 | -100.0% | $0.00 | 2025-Q2 |
| DODGE & COX | ADD | 3,016,425 | 5,534,624 | +83.5% | $612.1M | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 2,616,809 | 936,828 | -64.2% | $103.6M | 2025-Q1 |
| UBS Group AG | ADD | 419,428 | 785,501 | +87.3% | $86.9M | 2025-Q1 |
| FMR LLC | TRIM | 139,662 | 95,918 | -31.3% | $10.6M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 26,771 | 10,202 | -61.9% | $1.1M | 2025-Q1 |
| NORGES BANK | EXIT | 325,295 | 0 | -100.0% | $0.00 | 2025-Q1 |
| DODGE & COX | DOUBLED | 1,287,820 | 3,016,425 | +134.2% | $411.7M | 2024-Q4 |
| CITADEL ADVISORS LLC | ADD | 1,859,090 | 2,616,809 | +40.8% | $357.2M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 747,291 | — | $86.1M | 2024-Q3 |
15 unique insiders with 6 transactions. Net insider value: -$44.5M ($0.00 bought, $44.5M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 2, 2026 | Cooke Julie | Chief Human Resources Officer | M | 24,965 | $0.00 | $0.00 |
| Jun 2, 2026 | Cooke Julie | Chief Human Resources Officer | SELL | 14,214 | $154.83 | $2.2M |
| Jun 2, 2026 | Cooke Julie | Chief Human Resources Officer | M | 24,965 | $81.49 | $2.0M |
| Jun 2, 2026 | Keswani Sanjay Chandru | Chief Medical Officer | M | 3,212 | $0.00 | $0.00 |
| Jun 2, 2026 | Keswani Sanjay Chandru | Chief Medical Officer | F | 1,733 | $154.84 | $268.3K |
| Jun 2, 2026 | Keswani Sanjay Chandru | Chief Medical Officer | M | 3,212 | $0.00 | $0.00 |
| Jun 1, 2026 | Onyia Jude | Chief Scientific Officer | SELL | 11,000 | $160.25 | $1.8M |
| Jun 1, 2026 | Onyia Jude | Chief Scientific Officer | M | 11,000 | $84.74 | $932.1K |
| Jun 1, 2026 | Onyia Jude | Chief Scientific Officer | M | 11,000 | $0.00 | $0.00 |
| May 29, 2026 | Delaet Ingrid | Chief Regulatory Officer | M | 2,261 | $79.02 | $178.7K |
| May 29, 2026 | Delaet Ingrid | Chief Regulatory Officer | SELL | 2,261 | $156.71 | $354.3K |
| May 29, 2026 | Delaet Ingrid | Chief Regulatory Officer | M | 2,261 | $0.00 | $0.00 |
| May 27, 2026 | POON CHRISTINE A | Director | A | 2,567 | $0.00 | $0.00 |
| May 27, 2026 | Mercier Johanna | Director | A | 2,567 | $0.00 | $0.00 |
| May 27, 2026 | Norwalk Leslie V | Director | A | 1,284 | $0.00 | $0.00 |
| May 27, 2026 | Norwalk Leslie V | Director | A | 2,624 | $0.00 | $0.00 |
| May 27, 2026 | RASTETTER WILLIAM H | Director | A | 2,567 | $0.00 | $0.00 |
| May 27, 2026 | MORROW GEORGE J | Director | A | 2,567 | $0.00 | $0.00 |
| May 27, 2026 | SHERWIN STEPHEN A | Director | A | 2,567 | $0.00 | $0.00 |
| May 27, 2026 | Sharp Shalini | Director | A | 2,567 | $0.00 | $0.00 |
| May 27, 2026 | LYONS GARY A | Director | A | 1,284 | $0.00 | $0.00 |
| May 27, 2026 | LYONS GARY A | Director | A | 2,624 | $0.00 | $0.00 |
| May 27, 2026 | POPS RICHARD F | Director | A | 2,567 | $0.00 | $0.00 |
| May 27, 2026 | GORMAN KEVIN CHARLES | Director | A | 5,248 | $0.00 | $0.00 |
| May 27, 2026 | Onyia Jude | Chief Scientific Officer | M | 11,000 | $84.74 | $932.1K |
| May 27, 2026 | Onyia Jude | Chief Scientific Officer | SELL | 11,000 | $155.53 | $1.7M |
| May 27, 2026 | Onyia Jude | Chief Scientific Officer | M | 11,000 | $0.00 | $0.00 |
| May 26, 2026 | Boyer David W. | Chief Corp. Affairs Officer | SELL | 3,888 | $156.64 | $609.0K |
| May 21, 2026 | LYONS GARY A | Director | M | 1,659 | $0.00 | $0.00 |
| May 21, 2026 | Mercier Johanna | Director | M | 3,318 | $0.00 | $0.00 |
| May 21, 2026 | Mercier Johanna | Director | M | 3,318 | $0.00 | $0.00 |
| May 21, 2026 | MORROW GEORGE J | Director | M | 3,318 | $0.00 | $0.00 |
| May 21, 2026 | MORROW GEORGE J | Director | M | 3,318 | $0.00 | $0.00 |
| May 21, 2026 | Norwalk Leslie V | Director | M | 1,659 | $0.00 | $0.00 |
| May 21, 2026 | Norwalk Leslie V | Director | M | 1,659 | $0.00 | $0.00 |
| May 21, 2026 | POON CHRISTINE A | Director | M | 3,318 | $0.00 | $0.00 |
| May 21, 2026 | POPS RICHARD F | Director | M | 3,318 | $0.00 | $0.00 |
| May 21, 2026 | Sharp Shalini | Director | M | 1,659 | $0.00 | $0.00 |
| May 21, 2026 | POON CHRISTINE A | Director | M | 3,318 | $0.00 | $0.00 |
| May 21, 2026 | POPS RICHARD F | Director | M | 3,318 | $0.00 | $0.00 |
| May 21, 2026 | RASTETTER WILLIAM H | Director | M | 3,318 | $0.00 | $0.00 |
| May 21, 2026 | RASTETTER WILLIAM H | Director | M | 3,318 | $0.00 | $0.00 |
| May 21, 2026 | SHERWIN STEPHEN A | Director | M | 3,318 | $0.00 | $0.00 |
| May 21, 2026 | Sharp Shalini | Director | M | 1,659 | $0.00 | $0.00 |
| May 21, 2026 | SHERWIN STEPHEN A | Director | M | 3,318 | $0.00 | $0.00 |
| May 21, 2026 | LYONS GARY A | Director | M | 1,659 | $0.00 | $0.00 |
| May 19, 2026 | GORMAN KEVIN CHARLES | Director | M | 205,088 | $43.24 | $8.9M |
| May 19, 2026 | GORMAN KEVIN CHARLES | Director | SELL | 245,088 | $154.33 | $37.8M |
| May 19, 2026 | GORMAN KEVIN CHARLES | Director | M | 205,088 | $0.00 | $0.00 |
| May 15, 2026 | POPS RICHARD F | Director | M | 15,000 | $47.89 | $718.4K |
11 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 0 mixed, 8 neutral. Avg impact: 4.0/10.
NEUTRAL
CLUSTER
3/10
Four NBIX C-suite insiders sold a total of $4.93M in open-market shares over a 7-day window, with th
Jun 4, 2026
NEUTRAL
CLUSTER
2/10
Three C-suite officers at Neurocrine Biosciences sold a total of ~$2.73M in open-market shares withi
Jun 4, 2026
NEUTRAL
CLUSTER
3/10
Three Neurocrine executives (CSO, Chief Corp. Affairs Officer, Chief Regulatory Officer) sold a tota
Jun 2, 2026
NEUTRAL
CLUSTER
2/10
Three NBIX insiders, including the Chief Scientific Officer, sold a combined $2.67M in open-market s
Jun 2, 2026
NEUTRAL
CLUSTER
3/10
Two Neurocrine executives sold shares totaling $2.32M in the week following the close of the $2.9B S
May 29, 2026
NEUTRAL
CLUSTER
4/10
Two Neurocrine insiders sold a combined $38.43M in shares over the past week, with Director Kevin Go
May 28, 2026
NEUTRAL
CLUSTER
4/10
Two directors sold $40.2M in NBIX shares ($2.36M and $37.82M) within days of Neurocrine's $2.9B acqu
May 21, 2026
BEARISH
CLUSTER
5/10
Two NBIX directors sold shares totaling ~$40.8M following the closing of the $2.9B Soleno acquisitio
May 21, 2026
NEUTRAL
CLUSTER
3/10
Two NBIX directors sold $2.96M in shares over a 4-day window, representing a trivial 0.019% of marke
May 18, 2026
BULLISH
8-K
7/10
Neurocrine Biosciences closed its $2.9B acquisition of Soleno Therapeutics on May 18, 2026, adding V
May 18, 2026
BULLISH
8-K
8/10
Neurocrine Biosciences (NBIX) has entered into a definitive agreement to acquire Soleno Therapeutics
Apr 6, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (86% buy). Based on 36 analysts: 14 strong buy, 17 buy, 5 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$192.88 mean target
+17.7% upside
Buy (1.41)
$144.00 Low
$250.65 High
| Metric | Value |
|---|---|
| Current Price | $163.88 |
| Target Low | $144.00 |
| Target Mean | $192.88 |
| Target Median | $188.00 |
| Target High | $250.65 |
| # Analysts | 29 |
| Recommendation | Buy (1.41) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$2.11 | $1.67 | $2.81 | 28.0% | +9.9% | 11↑ 2↓ | $0.9B | 25.7% | 14 |
| Next Q 2026-09-30 |
$3.37 | $2.00 | $9.96 | 55.2% | +58.7% | 3↑ 0↓ | $1.0B | 27.7% | 11 |
| Current FY 2026-12-31 |
$10.27 | $8.27 | $17.37 | 60.6% | +33.8% | 5↑ 0↓ | $3.8B | 31.7% | 11 |
| Next FY 2027-12-31 |
$12.71 | $8.54 | $20.06 | 23.8% | -0.1% | 4↑ 0↓ | $4.5B | 19.6% | 11 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $2.112 | |
| 7d ago | $1.946 | +0.166 |
| 30d ago | $1.921 | +0.191 |
| 60d ago | $1.992 | +0.119 |
| 90d ago | $2.223 | -0.112 |
19 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 29, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| May 22, 2026 | Bernstein | INITIATE | — | Outperform |
| May 8, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| May 7, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| May 6, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| May 6, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| May 6, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| May 6, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| May 6, 2026 | Guggenheim | REITERATE | Buy | Buy |
| May 6, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Apr 22, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Apr 10, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| Apr 7, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Apr 7, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Apr 7, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Apr 7, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 6, 2026 | Needham | REITERATE | Buy | Buy |
| Mar 12, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Feb 24, 2026 | Wolfe Research | INITIATE | — | Outperform |
| Feb 17, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Feb 17, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Feb 13, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Feb 12, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Feb 12, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Feb 12, 2026 | BMO Capital | MAINTAIN | Market Perform | Market Perform |
| Feb 12, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Feb 12, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 12, 2026 | Needham | MAINTAIN | Buy | Buy |
| Jan 23, 2026 | UBS | MAINTAIN | Buy | Buy |
| Jan 12, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Jan 8, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Jan 8, 2026 | Morgan Stanley | DOWNGRADE | Overweight | Equal-Weight |
| Dec 17, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 12, 2025 | Mizuho | MAINTAIN | Neutral | Neutral |
| Dec 11, 2025 | Stifel | MAINTAIN | Buy | Buy |
| Dec 8, 2025 | RBC Capital | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 14 | 17 | 5 | 0 | 0 | 86% | |
| May 1, 2026 | 13 | 17 | 5 | 0 | 0 | 86% | |
| Apr 1, 2026 | 13 | 18 | 5 | 0 | 0 | 86% | |
| Mar 1, 2026 | 13 | 18 | 5 | 0 | 0 | 86% | |
| Feb 1, 2026 | 12 | 18 | 5 | 0 | 0 | 86% | |
| Jan 1, 2026 | 12 | 19 | 4 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 3, 2026
short_volume
Short Volume: NBIX — 60.5% short (0.4M / 0.7M)
Short: 445,235 | Exempt: 33,206 | TRF Vol: 736,399 | Short Ratio: 60.5% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: NBIX — 66.4% short (0.4M / 0.6M)
Short: 410,045 | Exempt: 17,469 | TRF Vol: 617,979 | Short Ratio: 66.4% | Off-exchange volume (dark pool + OTC)
May 28, 2026
Clinical Trial
Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE
Phase Phase 2 — TERMINATED
May 18, 2026
short_volume
Short Volume: NBIX — 81.4% short (0.4M / 0.5M)
Short: 438,793 | Exempt: 962 | TRF Vol: 538,922 | Short Ratio: 81.4% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: NBIX — 74.0% short (0.5M / 0.6M)
Short: 460,863 | Exempt: 5,534 | TRF Vol: 622,985 | Short Ratio: 74.0% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: NBIX — 66.7% short (0.4M / 0.6M)
Short: 382,995 | Exempt: 10,454 | TRF Vol: 573,940 | Short Ratio: 66.7% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_interest
FTD: NBIX — 30,536 shares ($4.9M) failed to deliver
Settlement: 20260514, Price: $161.32, FTD Value: $4,926,067.52, NEUROCRINE BIOSCIENCES INC
May 13, 2026
short_interest
FTD: NBIX — 28,599 shares ($4.5M) failed to deliver
Settlement: 20260513, Price: $155.80, FTD Value: $4,455,724.2, NEUROCRINE BIOSCIENCES INC
May 12, 2026
short_volume
Short Volume: NBIX — 61.3% short (0.3M / 0.5M)
Short: 329,416 | Exempt: 22,534 | TRF Vol: 537,653 | Short Ratio: 61.3% | Off-exchange volume (dark pool + OTC)
May 11, 2026
short_volume
Short Volume: NBIX — 66.2% short (0.3M / 0.5M)
Short: 333,876 | Exempt: 29,169 | TRF Vol: 504,019 | Short Ratio: 66.2% | Off-exchange volume (dark pool + OTC)
May 11, 2026
dark_pool
Dark Pool: NBIX — 2.2M shares, 48,658 trades
Week starting 2026-05-11. Total ATS volume: 2,211,461 shares across 48,658 trades.
May 8, 2026
short_volume
Short Volume: NBIX — 71.8% short (0.4M / 0.6M)
Short: 420,841 | Exempt: 9,499 | TRF Vol: 586,068 | Short Ratio: 71.8% | Off-exchange volume (dark pool + OTC)
May 7, 2026
short_volume
Short Volume: NBIX — 73.4% short (0.6M / 0.8M)
Short: 552,854 | Exempt: 53,666 | TRF Vol: 753,146 | Short Ratio: 73.4% | Off-exchange volume (dark pool + OTC)
May 7, 2026
short_interest
FTD: NBIX — 11,883 shares ($1.7M) failed to deliver
Settlement: 20260507, Price: $147.02, FTD Value: $1,747,038.66, NEUROCRINE BIOSCIENCES INC
May 6, 2026
short_volume
Short Volume: NBIX — 56.8% short (0.6M / 1.0M)
Short: 594,108 | Exempt: 24,269 | TRF Vol: 1,046,600 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
May 5, 2026
earnings_calendar
NBIX Q1 2026 Earnings Scheduled — 2026-05-05
Apr 29, 2026
Clinical Trial
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
Phase Phase 3 — COMPLETED
Apr 17, 2026
FDA
INGREZZA
WARNING: DEPRESSION AND SUICIDAL IDEATION AND BEHAVIOR IN PATIENTS WITH HUNTINGTON’S DISEASE VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKL
Apr 1, 2026
Clinical Trial
Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia
Phase Phase 3 — COMPLETED
Apr 30, 2024
FDA
INGREZZA SPRINKLE
Original Approval — Type 3 - New Dosage Form — VALBENAZINE — CAPSULE — ORAL